Meeting
2023 ASCO Gastrointestinal Cancers Symposium
NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).
Authors
Michael J. Overman
NSABP/NRG Oncology and University of Texas MD Anderson Cancer Center, and SWOG, Houston, TX;
Michael J. Overman , Greg Yothers , Samuel A. Jacobs , Hanna Kelly Sanoff , Deirdre Jill Cohen , Katherine A Guthrie , Norah Lynn Henry , Patricia A. Ganz , Scott Kopetz , Peter C. Lucas , Charles David Blanke , Theodore S. Hong , Norman Wolmark , Howard S. Hochster , Thomas J. George , Caio Max Sao Pedro Rocha Lima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05080673
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS258)
DOI
10.1200/JCO.2023.41.4_suppl.TPS258
Abstract #
TPS258
Poster Bd #
N20
Abstract Disclosures
Similar Posters
First Author: Caio Max Sao Pedro Rocha Lima
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).
First Author: Caio Max Sao Pedro Rocha Lima
First Author: James J. Lee
First Author: Michael J. Overman